Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market - 2022-2029

Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market - 2022-2029:

Market Overview

Angiotensin-Converting Enzyme (ACE) Inhibitors Market size was valued US$ 5,742.32 million in 2021 and is estimated to reach US$ YY billion by 2029, growing at a CAGR of 3.1% during the forecast period (2022-2029).

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) are high blood pressure drugs that widen or dilate the blood vessels to improve the amount of blood the heart pumps and to lower blood pressure. ACE inhibitors are primarily used to treat hypertension (elevated blood pressure) and congestive heart failure.

Market Dynamics

The growth of the market is majorly driven by increasingly being adopted globally owing to the increase in the prevalence of heart failures and the rising adoption of antihypertensive medicines. In addition, the rise in the adoption of Lisinopril drugs for treating high blood pressure, the rise in the demand for angiotensin-converting enzyme inhibitors with high angiotensin-converting enzyme affinity, the growing adoption of Perindopril drugs for hypertension, and the rise in the research and development activities for developing advanced drugs necessitated the growth of the global angiotensin-converting enzyme (ACE) inhibitors market.

Rising prevalence of cardiovascular diseases (ACE) Inhibitors are expected to drive market growth

According to statistics from the World Health Organization (WHO) for 2020, ischemic heart disease is to blame for 16% of all fatalities worldwide. According to a February 2020 article titled ""Heart failure (HF) in France: Chronic Heart Failure Therapeutic Management and Risk of Cardiac Decompensation in Real-Life Setting,"" approximately one million people in France would be affected by HF. Despite well-defined treatment management, there are nearly 70,000 HF-related deaths and more than 150,000 hospitalizations.

Introduction of new innovative products for treating hypertension-are a major factor driving the ACE Inhibitors Market size. Use of new therapies containing Coversyl (having perindopril arginine), Coversyl plus (having perindopril arginine, and indapamide hemihydrate), which are those chemicals that help in treatment. The continuum of cardiovascular disease begins with risk factors, such as hypertension, and progresses to atherosclerosis and target organ damage, ultimately leading to heart failure or stroke. Angiotensin-converting enzyme (ACE) inhibitors have become vital tools in the medical therapy of hypertension and cardiovascular disease. Evidence from clinical trials has shown that ACE inhibitors have the broadest impact of any drug in cardiovascular medicine, reducing the risk of death, myocardial infarction, stroke, diabetes, and renal impairment. They benefit patients with heart failure or left ventricular dysfunction, post-myocardial infarction, peripheral vascular disease, diabetes, stroke, transient ischaemic attack, or coronary artery disease.

The high cost of ACE inhibitors is one of the major factors hindering the growth of the market

The key companies in the market are increasing their investment to carry out various research and development activities for developing Lisinopril drugs for treating high blood pressure. However, the cost of ACE inhibitors ranges from $15 to $30, one of the major factors estimated to restrain the growth of the ACE inhibitors market.

COVID-19 Impact Analysis

The health industry was significantly impacted by COVID. Many nations are still attempting to defeat this pathogen. Wealth-related difficulties emerged in the sector. There was a noticeable financial downturn in developing and poor nations. Although the ACE Inhibitors Market had a significant fall, people with heart disease benefited from it. The healthcare regulations proposed by the administrations contained holistic mandates.

The nation's administration took the initiative to enforce a lockdown in order to address the crisis. To prevent this disintegration, he used a different strategy while keeping the social and economic spheres in balance. The government contributed funding to conduct the study that provides useful advice.

Also, in March 13, 2020, La Jolla Pharmaceutical Company, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, declared that it is providing GIAPREZA (angiotensin II) in Italy for compassionate use in patients with septic shock associated with COVID-19.

Industry Analysis

The global angiotensin-converting enzyme (ACE) inhibitors market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, reimbursement analysis, supply chain analysis, pricing analysis, technological advancements etc.

Segment Analysis

Dicarboxylate containing ACEI segment is expected to hold the largest market share in global angiotensin-converting enzyme (ACE) inhibitors market

Dicarboxylate containing ACEI segment includes benazepril, enalapril, lisinopril, perindopril, quinapril, ramipril, and trandolapril. These structural differences affect pharmacodynamic/pharmacokinetic profiles and determine the relative effectiveness of any given ACEI inhibitor on the Angiotensin I- and bradykinin-mediated pathways. For example, in vitro bradykinin/Angiotensin I selectivity ratio is higher for perindoprilat than for ramiprilat, quinaprilat, trandolaprilat and enalaprilat. Hicks et al. reported that the most commonly used ACEIs in their cohort was ramipril (26%), lisinopril (12%) and perindopril (7%).

Geographical Analysis

North America region holds the largest market share in the global angiotensin-converting enzyme (ACE) inhibitors market

North America is dominating the global angiotensin-converting enzyme (ACE) inhibitors market, accounting for the largest market share in 2020, owing to rising heart diseases, high obesity in the population, supportive reimbursement policies, and increasing R&D activities for the development of new drugs for the treatment. Heart disease is the leading cause of mortality in the United States, followed closely by cancer and chronic respiratory diseases. Heart disease causes almost 1 in 4 deaths in the U.S. In the U.S., about 697,000 people in the died from heart disease in 2020. Besides, the developed healthcare infrastructure and high public awareness related to diagnosis, treatment, and management of lifestyle diseases boost the growth of the ACE inhibitors market in this region. Moreover, the need for angiotensin-converting enzyme inhibitors and the expansion of research and development efforts for creating improved inhibitors are two aspects that have contributed to the growth of this market. The ACE Inhibitors Market is expanding as more people turn to lisinopril to increase their chances of surviving a heart attack. Statistics show that there have been 33.6 million more visits to doctor's offices with hypertension as the major diagnosis.

Competitive Landscape

The angiotensin-converting enzyme (ACE) inhibitors market is highly competitive, owing to the presence of big brands. Also, the market is highly fragmented due to the presence of several large and regional players. The key players which are contributing to the growth of the global market include Pfizer, Merck, Novartis, Sanofi, Abbott Laboratories Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Johnson and Johnson, and Teva Pharmaceutical. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the growth of the angiotensin-converting enzyme (ACE) Inhibitors market globally. For instance, in August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults

Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market – Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio: Tarka (trandolapril / verapamil) is a combination medication containing trandolapril (ACE inhibitor) and verapamil (calcium channel blocker). These two medications work together to lower blood pressure, though it is not a first-choice option.

The global angiotensin-converting enzyme (ACE) inhibitors market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.